Aspirin use Reduces Platelet Hyperreactivity and Degranulation in COVID-19 Patients

Younes Zaid; Qamar Lahlimi; Loubna Khalki; Nabil Zaid; Mounia Oudghiri; Amine Cheikh; Abdallah Naya; Yahye Merhi; Fadila Guessous

doi:10.1055/s-0042-1744281

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2023; 49(01): 092-096
DOI: 10.1055/s-0042-1744281

Letter to the Editor

Aspirin use Reduces Platelet Hyperreactivity and Degranulation in COVID-19 Patients

Authors

Younes Zaid^*

¹Department of Biology, Faculty of Sciences, Mohammed V University in Rabat, Rabat, Morocco

²Research Center of Abulcasis University of Health Sciences, Rabat, Morocco

³Immunology and Biodiversity Laboratory, Department of Biology, Faculty of Sciences, Hassan II University, Casablanca, Morocco
Qamar Lahlimi^*

¹Department of Biology, Faculty of Sciences, Mohammed V University in Rabat, Rabat, Morocco
Loubna Khalki

⁴Laboratory of Thrombosis and Hemostasis, Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada
Nabil Zaid

¹Department of Biology, Faculty of Sciences, Mohammed V University in Rabat, Rabat, Morocco
Mounia Oudghiri

³Immunology and Biodiversity Laboratory, Department of Biology, Faculty of Sciences, Hassan II University, Casablanca, Morocco
Amine Cheikh

²Research Center of Abulcasis University of Health Sciences, Rabat, Morocco
Abdallah Naya

³Immunology and Biodiversity Laboratory, Department of Biology, Faculty of Sciences, Hassan II University, Casablanca, Morocco
Yahye Merhi

⁴Laboratory of Thrombosis and Hemostasis, Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada
Fadila Guessous

⁵Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco

Abstract

Full Text

References

References
1 Allaoui A, Khawaja AA, Badad O. et al. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021; 47 (04) 419-426
2 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
3 Llitjos JF, Leclerc M, Chochois C. et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18 (07) 1743-1746
4 Rapkiewicz AV, Mai X, Carsons SE. et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine 2020; 24: 100434
5 Pellegrini D, Kawakami R, Guagliumi G. et al. Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study. Circulation 2021; 143 (10) 1031-1042
6 Zaid Y, Puhm F, Allaeys I. et al. Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19. Circ Res 2020; 127 (11) 1404-1418
7 Zaid Y, Guessous F, Puhm F. et al. Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19. Blood Adv 2021; 5 (03) 635-639
8 Limami Y, Khalki L, Zaid N. et al. Oxford-AstraZeneca ChAdOx1 COVID-19 vaccine does not alter platelet aggregation. Semin Thromb Hemost 2022; 48 (01) 109-111
9 Zhang S, Liu Y, Wang X. et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol 2020; 13 (01) 120
10 Shen S, Zhang J, Fang Y. et al. SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism. J Hematol Oncol 2021; 14 (01) 72
11 Zaid Y, Doré É, Dubuc I. et al. Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. J Allergy Clin Immunol 2021; 148 (02) 368-380.e3
12 Koupenova M, Corkrey HA, Vitseva O. et al. SARS-CoV-2 initiates programmed cell death in platelets. Circ Res 2021; 129 (06) 631-646
13 Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96 (08) 2751-2753
14 Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004; 43 (06) 979-984
15 Boulaftali Y, Hess PR, Getz TM. et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest 2013; 123: 908-916
16 Boulaftali Y, Hess PR, Kahn ML, Bergmeier W. Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity. Circ Res 2014; 114 (07) 1174-1184
17 Archambault AS, Zaid Y, Rakotoarivelo V. et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. FASEB J 2021; 35 (06) e21666
18 Chow JH, Khanna AK, Kethireddy S. et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg 2021; 132 (04) 930-941
19 Merzon E, Green I, Vinker S. et al. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. FEBS J 2021; 288 (17) 5179-5189
20 Abdulnour RE, Gunderson T, Barkas I. et al. Early intravascular events are associated with development of acute respiratory distress syndrome. A substudy of the LIPS-A clinical trial. Am J Respir Crit Care Med 2018; 197 (12) 1575-1585
21 Zaid Y, Marhoume F, Senhaji N. et al. Paraphenylene diamine exacerbates platelet aggregation and thrombus formation in response to a low dose of collagen. J Toxicol Sci 2016; 41 (01) 123-128
22 Hachem A, Yacoub D, Zaid Y, Mourad W, Merhi Y. Involvement of nuclear factor κB in platelet CD40 signaling. Biochem Biophys Res Commun 2012; 425 (01) 58-63
23 Manne BK, Denorme F, Middleton EA. et al. Platelet gene expression and function in patients with COVID-19. Blood 2020; 136 (11) 1317-1329
24 Taus F, Salvagno G, Canè S. et al. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia. Arterioscler Thromb Vasc Biol 2020; 40 (12) 2975-2989
25 Reese JT, Coleman B, Chan L. et al. Cyclooxygenase inhibitor use is associated with increased COVID-19 severity. medRxiv. 2021
26 Iacobucci G. Covid-19: aspirin does not improve survival for patients admitted to hospital, trial reports. BMJ 2021; 373 (1475): n1475
27 Cloutier N, Allaeys I, Marcoux G. et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proc Natl Acad Sci U S A 2018; 115 (07) E1550-E1559
28 Arif H, Aggarwal S. Salicylic Acid (Aspirin). Treasure Island, FL: StatPearls; 2021
29 Crescente M, Menke L, Chan MV, Armstrong PC, Warner TD. Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). Br J Pharmacol 2019; 176 (08) 988-999
30 Glatthaar-Saalmüller B, Mair KH, Saalmüller A. Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study. Influenza Other Respir Viruses 2017; 11 (01) 85-92
31 Hottz ED, Azevedo-Quintanilha IG, Palhinha L. et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 2020; 136 (11) 1330-1341